TScan Therapeutics Overview
- Year Founded
-
2018
- Status
-
Public
- Employees
-
199
- Stock Symbol
-
TCRX
- Share Price
-
$2.52
- (As of Friday Closing)
TScan Therapeutics General Information
Description
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
Contact Information
Website
www.tscan.comCorporate Office
- 830 Winter Street
- Waltham, MA 02451
- United States
Corporate Office
- 830 Winter Street
- Waltham, MA 02451
- United States
TScan Therapeutics Timeline
TScan Therapeutics Stock Performance
As of 24-Jan-2025, TScan Therapeutics’s stock price is $2.52. Its current market cap is $142M with 56.5M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.52 | $2.56 | $2.31 - $9.69 | $142M | 56.5M | 422K | -$0.95 |
TScan Therapeutics Financials Summary
As of 30-Sep-2024, TScan Therapeutics has a trailing 12-month revenue of $9.4M.
|
In Thousands, USD |
TTM 30-Sep-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | 57,207 | 150,378 | (66,083) | (68,945) |
| Revenue | 9,362 | 21,049 | 13,535 | 10,141 |
| EBITDA | (114,789) | (88,058) | (61,536) | (45,313) |
| Net Income | (111,303) | (89,218) | (66,221) | (48,625) |
| Total Assets | 348,027 | 272,149 | 199,091 | 188,107 |
| Total Debt | 90,356 | 92,433 | 85,984 | 6,043 |
TScan Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
TScan Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
TScan Therapeutics Comparisons
Industry
Financing
Details
TScan Therapeutics Competitors (52)
One of TScan Therapeutics’s 52 competitors is Fate Therapeutics, a Formerly VC-backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Fate Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| NexImmune | Formerly VC-backed | Gaithersburg, MD | ||||
| Instil Bio | Formerly VC-backed | Dallas, TX | ||||
| Kite Pharma | Formerly VC-backed | Santa Monica, CA | ||||
| Rein Therapeutics | Formerly VC-backed | Austin, TX |
TScan Therapeutics Patents
TScan Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023241307-A1 | Magea1 immunogenic peptides, binding proteins recognizing magea1 immunogenic peptides, and uses thereof | Active | 05-Oct-2022 | ||
| AU-2023241306-A1 | Prame immunogenic peptides, binding proteins recognizing prame immunogenic peptides, and uses thereof | Active | 05-Oct-2022 | ||
| AU-2023241306-B2 | Prame immunogenic peptides, binding proteins recognizing prame immunogenic peptides, and uses thereof | Active | 05-Oct-2022 | ||
| AU-2023241307-B2 | Magea1 immunogenic peptides, binding proteins recognizing magea1 immunogenic peptides, and uses thereof | Active | 05-Oct-2022 | ||
| AU-2024278650-A1 | Prame immunogenic peptides, binding proteins recognizing prame immunogenic peptides, and uses thereof | Pending | 05-Oct-2022 | A61P35/00 |
TScan Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
TScan Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
TScan Therapeutics FAQs
-
When was TScan Therapeutics founded?
TScan Therapeutics was founded in 2018.
-
Where is TScan Therapeutics headquartered?
TScan Therapeutics is headquartered in Waltham, MA.
-
What is the size of TScan Therapeutics?
TScan Therapeutics has 199 total employees.
-
What industry is TScan Therapeutics in?
TScan Therapeutics’s primary industry is Biotechnology.
-
Is TScan Therapeutics a private or public company?
TScan Therapeutics is a Public company.
-
What is TScan Therapeutics’s stock symbol?
The ticker symbol for TScan Therapeutics is TCRX.
-
What is the current stock price of TScan Therapeutics?
As of 24-Jan-2025 the stock price of TScan Therapeutics is $2.52.
-
What is the current market cap of TScan Therapeutics?
The current market capitalization of TScan Therapeutics is $142M.
-
What is TScan Therapeutics’s current revenue?
The trailing twelve month revenue for TScan Therapeutics is $9.4M.
-
Who are TScan Therapeutics’s competitors?
Fate Therapeutics, NexImmune, Instil Bio, Kite Pharma, and Rein Therapeutics are some of the 52 competitors of TScan Therapeutics.
-
What is TScan Therapeutics’s annual earnings per share (EPS)?
TScan Therapeutics’s EPS for 12 months was -$0.95.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
